This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SAN DIEGO, March 14, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (
www.apricusbio.com ) announced today that it will hold a conference call to discuss its year end 2012 financial results and recent corporate highlights on Monday, March 18, 2013 at 1:00 p.m. ET. The Company expects to file its Form 10-K for the year ended December 31, 2012 on Monday, March 18, 2013.
The call can be accessed in the U.S. by dialing 877-407-8031 and outside of the U.S. by dialing 201-689-8031 and asking the conference operator for the Apricus Bio Conference Call. The teleconference replay will be available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing 201-612-7415. Replay passcode 410469 is required for playback. The conference call will also be webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=170645 . The webcast replay will be available for three months.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which will be marketed in Canada by Abbott Laboratories, and Femprox®, a product candidate, for the treatment of female sexual arousal disorder, which successfully completed a nearly 400-subject Phase III study in China.
For further information on Apricus Bio, visit
http://www.apricusbio.com . You can also receive information at
CONTACT: Apricus Bio Investor Relations:
David Pitts or Lourdes Catala